Warberg Asset Management LLC Takes Position in Gain Therapeutics, Inc. (NASDAQ:GANX)

Warberg Asset Management LLC acquired a new stake in Gain Therapeutics, Inc. (NASDAQ:GANX) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 51,600 shares of the company’s stock, valued at approximately $66,000.

Separately, Hohimer Wealth Management LLC acquired a new position in Gain Therapeutics in the 2nd quarter valued at approximately $422,000. Hedge funds and other institutional investors own 11.97% of the company’s stock.

Insider Buying and Selling

In other news, Chairman Khalid Islam acquired 50,000 shares of Gain Therapeutics stock in a transaction on Friday, August 9th. The stock was purchased at an average price of $1.00 per share, with a total value of $50,000.00. Following the completion of the purchase, the chairman now owns 50,000 shares of the company’s stock, valued at approximately $50,000. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last three months, insiders have bought 81,400 shares of company stock valued at $85,284. 11.70% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on GANX shares. HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of Gain Therapeutics in a report on Tuesday, September 3rd. Chardan Capital reiterated a “buy” rating and set a $6.00 price objective on shares of Gain Therapeutics in a research report on Friday, August 9th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $8.00 price target on shares of Gain Therapeutics in a research report on Wednesday, August 14th.

Gain Therapeutics Price Performance

Shares of NASDAQ GANX opened at $1.47 on Friday. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.03. The firm has a market cap of $37.40 million, a PE ratio of -0.98 and a beta of 0.35. The company’s fifty day simple moving average is $1.18 and its 200 day simple moving average is $2.32. Gain Therapeutics, Inc. has a 12-month low of $0.89 and a 12-month high of $5.33.

Gain Therapeutics (NASDAQ:GANX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.11). As a group, sell-side analysts forecast that Gain Therapeutics, Inc. will post -1.05 earnings per share for the current fiscal year.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.